Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.
Regeneron is to pay $256 million in cash to acquire “substantially all” of 23andMe’s assets, including its massive biobank of around 15 million customer genetic samples and data.
Nope, and not even because of the current administration: this country is by, for, and about rich people, and people are getting deliriously rich off of our data right now so there’s no political will to do anything about it.